Katherine Newell, Nikki Vroom, Cátia Marques, Ekaterina Maslova, Farid L Khan, Kok-Yew Ngew, Hannah R Volkman, Chengbin Wang, Juan V […]
Author: Gert Verbeken
Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform
Hannah R. Volkman ,Leonie de Munter, Jennifer L. Nguyen, Thao M. P. Tran, Marianna Mitratza, Cátia Marques, Laura Choi, Srinivas […]
id.DRIVE launches pilot study to assess potential underestimation of RSV, hMPV, and PIV detection rates.
id.DRIVE launched a new prospective cohort pilot study to investigate whether respiratory syncytial virus (RSV) and other respiratory viruses may […]
Precautionary Health Behaviours as Potential Confounders in COVID-19 Vaccine Effectiveness Studies
Chloé Wyndham-Thomas, Leonie de Munter, Kok Yew Ngew, Sanskruti Gaikwad, Konstantina Chatzikonstantinidou, Antonio Carmona, Charlotte Martin, Gerrit Luit ten Kat, […]
The id.DRIVE studies reach 25,000 patients — A major milestone on our mission to build a large and sustainable platform for respiratory pathogens and vaccines research
We are proud to announce that the id.DRIVE partnership has officially recruited 25,000 patients across our three studies (surveillance, COVID-19 and RSV […]
Effectiveness of the AZD1222 Vaccine against COVID-19 hospitalisation in Europe: Final results from the COVIDRIVE test-negative case-control study.
Leonie de Munter, Wilhelmine Meeraus, Akshat Dwivedi, Marianna Mitratza, Chloé Wyndham-Thomas, Lucy Carty, Mario Ouwens, Wendy Hartig-Merkel, Laura Drikite, Griet […]
Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVEplatform.
Jennifer L. Nguyen, Marianna Mitratza, Hannah R. Volkman, Leonie de Munter, Thao Mai Phuong Tran, Catia Marques, Mustapha Mustapha, Srinivas […]
Protection against COVID-19 hospitalisation conferred by primary-series vaccination with AZD1222 in non-boosted individuals: first vaccine effectiveness results of the European COVIDRIVE study and meta-regression analysis.
Wilhelmine Meeraus, Leonie de Munter, Christen M. Gray, Akshat Dwivedi, Chloé Wyndham-Thomas, Mario Ouwens, Wendy Hartig-Merkel, Laura Drikite, Griet Rebry, […]
Durability of the BNT162b2 XBB.1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform” (pre-print).
HR Volkman, L de Munter, JL Nguyen, TMP Tran, M Mitratza, C Marques, L Choi, S Valluri, J Yang, A […]
The value of public-private collaborative real-world evidence platforms to monitor vaccine performance post authorization: DRIVE – a European initiative
Díez-Domingo J, Torcel-Pagnon L, Carmona A, Launay O, Dos Santos G, Rizzo C, Haag M, Stuurman A, Nauta J, Vannacci […]